Expert Interview
A Second Look: Digging into the positive results from the Phase 3 DeFi trial of Springworks Therapeutics' Nirogacestat in adult patients with progressive desmoid tumors.
Ticker(s): SWTXInstitution: Duke Cancer Center
- Associate Professor with Tenure in the Division of Medical Oncology at Duke University Medical Center & Associate Director for Clinical and Translational Research for the Duke Sarcoma Program.
- Treats 50 patients with desmoid tumors.
- Research focuses on identifying novel therapeutics for patients with soft tissue and bone sarcoma; serves as a member of the NCCN guideline committees for both soft tissue sarcoma and GIST.
Roughly how many patients do you manage with desmoid tumors?
Added By: sara_adminWhat were your key take aways from the results of Nirogacestat in the Phase 3 DeFi trial?
Added By: sara_adminOn a scale from 1-10 (10 being extremely excited) where would you rate your level of excitement for Nirogacestat?
Added By: sara_adminAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
